Vyant Bio (NASDAQ:VYNT), Inc (NASDAQ:VYNT) CEO Jay Roberts tells Proactive the Cherry Hill, New Jersey-based emerging global drug discovery company posted second-quarter results that demonstrated it is in a strong financial position with $26.5 million to build a “robust pipeline” of novel therapeutics targeting neurological disorders and cancers.
What's more, Roberts spoke about the group's recent merger between Stemonix Inc and Cancer Genetics Inc, and its subsequent rebranding to Vyant Bio (NASDAQ:VYNT).
Today, Vyant announced a collaboration combining its patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder.